Patients initiating semaglutide often have multiple cardiovascular risk factors, including obesity, diabetes, hypertension, and metabolic syndromeall conditions independently associated with cardiac arrhythmias and palpitations
The company also says its about to send cease and desist letters to about 50 more pharmacies and telehealth companies, demanding they immediately stop mass-producing any compounded versions
Handle all negotiations with pharmaceutical companies and their legal teams
Learn more The soothing effects of a sauna without the intense steam
Figures are created with Servier Medical Art and exported under a paid subscription
Source: Pocket Manual of Therapy (Bartoccioni et al.) / FDA and EMA Respiratory Updates (Tool failure - Internal Knowledge used) To view or add a comment, sign in The provided image outlines a clinical guideline for choosing medicines for Type 2 diabetes in adults, emphasizing a personalized treatment approach based on specific patient profiles
